How will the acquisition of Investiga boost ALS (ASX:ALQ) growth?

Source:Roman Zaiets ,Shutterstock


  • ALS Ltd (ASX:ALQ) is set to acquire Investiga, a pharmaceutical testing business.
  • Investiga would be integrated into its existing Life Sciences network with a focus on boosting its growth in the US.
  • Investiga’s acquisition significantly boosts the company’s presence in the pharmaceutical market.


ALS Ltd (ASX:ALQ) on Monday announced the acquisition of Investiga, a pharmaceutical testing business with operations in Brazil and the east coast of the US. The acquisition would be done for an undisclosed amount, which is eleven times adjusted FY2020 EBITDA, ALS said in its latest update. Investiga reported a revenue of A$20 million in FY2020.

Image Source: © Cammeraydave |

ALS, the global testing, inspection and certification business, said that Investiga would be integrated into its existing Life Sciences network with a focus on boosting its growth in the US.

What management says

Commenting on the acquisition, Managing Director and CEO, Raj Naran said that boosting the Life Sciences division was a key part of ALS strategy and Investiga would significantly enhance the company’s presence in the pharmaceutical market. ALS has a strong track record of integrating acquisitions into its Life Sciences network and Investiga provides it with the platform to grow the cosmetic and personal care offering, particularly in the US, Naran said.


Even amid the uncertainty triggered by the COVID-19 pandemic, ALS traded resiliently in the third and early fourth quarter. Life Sciences volumes remained stable as laboratories provided their essential services to clients in major markets. The commodities division has started to benefit from the improving cycle. Geochemistry sample flows increased by 13 per cent in Q3 FY21 and the momentum is expected to continue into early Q4. 

Image Source: © Cammeraydave |

Major miners along with junior and intermediate miners contributed to this growth, although proportionally unchanged from late Q2 FY21. In the Industrial division, Tribology had seen some improvement in the third quarter, while the trading environment for Asset Care remained challenging. The balance sheet was strong with in excess of A$600 million of liquidity and a leverage ratio of 1.7 times as on 31 January 2021.

READ MORE: Bitcoin Stays Below $50,000 As Worries Over Digital Yuan Resurface

Stock performance

On Friday, 5 March 2021, the shares of ALS closed at A$9.49, up 0.040 points, or 0.42 per cent, against the previous closing on Thursday, 4 March 2021.

READ MORE: EU To Ask the US to Export AstraZeneca/Oxford Vaccine: Report


The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK